CRH posts higher revenue and profit for full year 2025

0Comments

CRH, a major building materials supplier, released its financial results for the fourth quarter and full year 2025. The company reported total revenues of $37.4 billion for 2025, up 5% from $35.6 billion in 2024. This increase was attributed to strong demand in end markets, effective commercial strategies, and recent acquisitions.

Net income rose to $3.8 billion in 2025 from $3.5 billion the previous year, an increase of 8%. Adjusted EBITDA reached $7.7 billion, representing an 11% rise compared to $6.9 billion in 2024. The company’s net income margin improved slightly to 10.1%, while its adjusted EBITDA margin increased to 20.5%.

Jim Mintern, Chief Executive Officer of CRH, commented on the performance: “2025 proved to be a year of significant progress for CRH, with double-digit Adjusted EBITDA* growth and a 12th consecutive year of margin* expansion delivering another record performance and reinforcing our position as the leading compounder of capital in our industry. Our balance sheet strength, cash generation capabilities and disciplined approach to capital allocation enabled us to deploy $5.8 billion in value-accretive growth investments across our connected portfolio while also returning $2.2 billion to shareholders through dividends and share buybacks. We enter 2026 with confidence and expect favorable end-market dynamics as well as the continued execution of our superior strategy to underpin another year of growth and value creation for our shareholders.”

The company invested $5.8 billion in growth initiatives during the year and returned $2.2 billion to shareholders via dividends and share repurchases.

The results reflect ongoing momentum in pricing strategies and careful management of costs.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.